Most “DIY” patent searches don’t fail quietly—they fail expensively.
If you’re a pharma, biotech, medtech, or even a generic/brand team trying to move fast, it’s tempting to treat drug patent research like a scavenger hunt: plug in a few names, skim a …

Stop the DIY Patent Search: The FTO Opinion That Could Save You From “Willful” Infringement
In pharma, the most expensive mistake is often the one you don’t realize you made—because you thought you were being careful.
A growing number of companies are …

Pharma procurement teams are being asked to do something that sounds simple—and is anything but: “Just buy the drug cheaper.”
But the real question isn’t unit price. It’s total cost.
In a world where drug spend is scrutinized line-by-line, procurement …

Pharma doesn’t always “win” new drugs. Sometimes it wins time.
Drug patent term extensions—those often-overlooked legal mechanisms that can push exclusivity out by years—are quietly one of the biggest levers in the industry’s financial model. And in a …

Generic drugmakers don’t just “wait for patents to expire.” They litigate their way to the starting line.
That’s the core lesson from DrugPatentWatch’s “Hatch-Waxman Playbook,” a deep dive into how generic manufacturers use patent litigation as a str…

The real battleground in pharma isn’t the patent—it’s the contract.
Most teams treat “patent loss of exclusivity” as the finish line. In reality, it’s the starting gun for a different kind of competition: how quickly you can win formulary placement, se…

Old Drugs, New Signals: What the Side-Effect Conversation Is Really Saying
The side-effect conversation is getting louder. And it’s not just about pharmacovigilance anymore—it’s about strategy.
A new wave of commentary around “old drugs” and “new signa…

A drug patent isn’t “worth” what the market says—it’s worth what it can survive.
In M&A, we love clean narratives: a pipeline, a valuation model, a headline number. But when the asset is a patent—especially one tied to a blockbuster or a near-ter…

Most NDAs Don’t Fail on Science. They Fail on Strategy.
In pharma, we love to talk about molecules—mechanisms, trial design, endpoints, and the elegance of the data. But anyone who’s shepherded an NDA knows the uncomfortable truth: the submission is …

Two clocks. One drug. And a deadline that can make or break your pipeline.
In pharma, timing isn’t just strategy—it’s survival.
A single product can be governed by two different clocks that start ticking at different moments, run on different rules, an…